Efficacy of supraglottic airway devices in chest compression synchronized ventilation during continuous resuscitation: a prospective randomized cross-over cadaver study
Tamar Gelashvili, Beate Brand‐Saberi, Mahsa Darvishali, Annika Hoyer, Lydia Johnson Kolaparambil Varghese, Vanessa Kuehn, Julius Lohmann, Christian Neuhaus, Cláudia Dornelles Schneider, Justin Trenkel, Jochen Hinkelbein, Gerrit Jansen
Abstract
BACKGROUND: This study aimed to evaluate the efficacy of Chest-Compression-Synchronized-Ventilation (CCSV) using supraglottic airway devices (SGA) compared to tracheal intubation (TI) for ventilation during continuous resuscitation. METHODS: ). Logistic regression models with random intercepts were used for the primary outcome, and linear mixed models were applied for secondary outcomes. RESULTS: (RC = -55.03 %; 95 %CI = [-62.92-47.15]; p < 0.0001). In comparisons among the individual SGA, lower pCCSV-values were observed for Ambu®AuraGain™ versus I-GEL® (RC = -2.58 mbar; 95 %CI = [-4.04--1.13]; p = 0.0006), Ambu®AuraGain™ versus LTS-D® (RC = -1.73 mbar; 95 %CI = [-3.18--0.27]; p = 0.0204), and LTS-D® versus I-GEL® (RC = -0.86 mbar; 95 %CI = [-2.30-0.59]; p = 0.2434). CONCLUSION: . Regardless the airway device, CCSV-failure is possible emphasizing the need for vigilant respiratory monitoring. REGISTRATION: URL: https://www. CLINICALTRIALS: gov. Unique identifier number: NCT06306898.